A novel mutation in the transmembrane nonpore region of the KCNH2 gene causes severe clinical manifestations of long QT syndrome.

[1]  S. Priori,et al.  Sudden cardiac death and genetic ion channelopathies: long QT, Brugada, short QT, catecholaminergic polymorphic ventricular tachycardia, and idiopathic ventricular fibrillation. , 2012, Circulation.

[2]  Yingying Tang,et al.  Partially Dominant Mutant Channel Defect Corresponding with Intermediate LQT2 Phenotype , 2012, Pacing and clinical electrophysiology : PACE.

[3]  W. Kitagawa,et al.  Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice , 2010, Clinical and Experimental Nephrology.

[4]  E. Kaufman,et al.  Genotype-phenotype aspects of type 2 long QT syndrome. , 2009, Journal of the American College of Cardiology.

[5]  M. Horie,et al.  Latent Genetic Backgrounds and Molecular Pathogenesis in Drug-Induced Long-QT Syndrome , 2009, Circulation. Arrhythmia and electrophysiology.

[6]  Z. Jia,et al.  Extracellular K+ concentration controls cell surface density of IKr in rabbit hearts and of the HERG channel in human cell lines. , 2009, The Journal of clinical investigation.

[7]  Chang-cong Cui,et al.  HERG‐F463L POTASSIUM CHANNELS LINKED TO LONG QT SYNDROME REDUCE IKr CURRENT BY A TRAFFICKING‐DEFICIENT MECHANISM , 2009, Clinical and experimental pharmacology & physiology.

[8]  A. Shelling,et al.  Misdiagnosis of long QT syndrome as epilepsy at first presentation. , 2009, Annals of emergency medicine.

[9]  G. Cascino,et al.  Identification of a possible pathogenic link between congenital long QT syndrome and epilepsy , 2009, Neurology.

[10]  I. Deschênes,et al.  A new C-terminal hERG mutation A915fs+47X associated with symptomatic LQT2 and auditory-trigger syncope. , 2008, Heart rhythm.

[11]  Zaiqi Wang,et al.  Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers. , 2007, Clinical therapeutics.

[12]  P. C. Viswanathan,et al.  HERG Is Protected from Pharmacological Block by α-1,2-Glucosyltransferase Function* , 2007, Journal of Biological Chemistry.

[13]  A. Moss,et al.  Corrected QT variability in serial electrocardiograms in long QT syndrome: the importance of the maximum corrected QT for risk stratification. , 2006, Journal of the American College of Cardiology.

[14]  C. January,et al.  Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism , 2006, Circulation.

[15]  D. Roden.  Long QT syndrome: reduced repolarization reserve and the genetic link , 2006, Journal of internal medicine.

[16]  P. C. Viswanathan,et al.  Genetics of acquired long QT syndrome. , 2005, The Journal of clinical investigation.

[17]  K. Hayashi,et al.  Probucol aggravates long QT syndrome associated with a novel missense mutation M124T in the N-terminus of HERG. , 2004, Clinical science.

[18]  C. January,et al.  Pharmacological rescue of trafficking defective HERG channels formed by coassembly of wild-type and long QT mutant N470D subunits. , 2004, American Journal of Physiology. Heart and Circulatory Physiology.

[19]  D. Roden,et al.  IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  C. January,et al.  Thapsigargin Selectively Rescues the Trafficking Defective LQT2 Channels G601S and F805C* , 2003, Journal of Biological Chemistry.

[21]  K. Hayashi,et al.  Characterization of a novel missense mutation E637K in the pore-S6 loop of HERG in a patient with long QT syndrome. , 2002, Cardiovascular research.

[22]  Derick R. Peterson,et al.  Increased Risk of Arrhythmic Events in Long-QT Syndrome With Mutations in the Pore Region of the Human Ether-a-go-go–Related Gene Potassium Channel , 2002, Circulation.

[23]  R. Elston,et al.  Electrocardiographic Prediction of Abnormal Genotype in Congenital Long QT Syndrome: Experience in 101 Related Family Members , 2001, Journal of cardiovascular electrophysiology.

[24]  C. January,et al.  Long QT Syndrome: , 2000, Journal of cardiovascular electrophysiology.

[25]  A J Moss,et al.  Spectrum of Mutations in Long-QT Syndrome Genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 , 2000, Circulation.

[26]  Jeffrey R. Balser,et al.  A sensitive mechanism for cation modulation of potassium current , 2000, Nature Neuroscience.

[27]  C. January,et al.  Correction of Defective Protein Trafficking of a Mutant HERG Potassium Channel in Human Long QT Syndrome , 1999, The Journal of Biological Chemistry.

[28]  R. Nagai,et al.  Novel mechanism of HERG current suppression in LQT2: shift in voltage dependence of HERG inactivation. , 1998, Circulation research.

[29]  D M Roden,et al.  Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. , 1997, Circulation research.

[30]  M. Sanguinetti,et al.  Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Moss,et al.  The Long QT Syndrome: Prospective Longitudinal Study of 328 Families , 1991, Circulation.

[32]  K. Hayashi,et al.  A KCR1 variant implicated in susceptibility to the long QT syndrome. , 2011, Journal of molecular and cellular cardiology.

[33]  D J Triggle,et al.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.

[34]  J. Weiss,et al.  Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. , 1996, Journal of the American College of Cardiology.